Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.0 - $44.95 $0 - $1.09 Million
-24,200 Closed
0 $0
Q4 2022

Feb 14, 2023

SELL
$18.01 - $23.78 $970,739 - $1.28 Million
-53,900 Reduced 69.01%
24,200 $522,000
Q3 2022

Nov 14, 2022

BUY
$16.32 - $26.37 $1.27 Million - $2.06 Million
78,100 New
78,100 $1.51 Million
Q2 2022

Aug 15, 2022

SELL
$18.54 - $37.29 $3.14 Million - $6.32 Million
-169,600 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$23.94 - $33.74 $2.89 Million - $4.07 Million
120,710 Added 246.9%
169,600 $5.06 Million
Q4 2021

Feb 14, 2022

BUY
$21.19 - $31.29 $1.04 Million - $1.53 Million
48,890 New
48,890 $1.14 Million
Q3 2020

Nov 16, 2020

SELL
$23.19 - $41.61 $4.06 Million - $7.28 Million
-175,000 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$14.82 - $29.92 $5.04 Million - $10.2 Million
-340,000 Reduced 66.02%
175,000 $4.64 Million
Q1 2020

May 15, 2020

BUY
$11.67 - $27.23 $3.54 Million - $8.25 Million
302,970 Added 142.89%
515,000 $8.43 Million
Q4 2019

Feb 14, 2020

BUY
$16.92 - $28.96 $2.1 Million - $3.59 Million
124,124 Added 141.2%
212,030 $5.39 Million
Q3 2019

Nov 15, 2019

SELL
$20.0 - $31.88 $1.58 Million - $2.52 Million
-79,058 Reduced 47.35%
87,906 $1.76 Million
Q2 2019

Aug 14, 2019

SELL
$30.67 - $37.86 $507,005 - $625,863
-16,531 Reduced 9.01%
166,964 $5.38 Million
Q1 2019

May 15, 2019

BUY
$22.22 - $32.21 $3.77 Million - $5.47 Million
169,795 Added 1239.38%
183,495 $5.91 Million
Q4 2018

Feb 14, 2019

BUY
$20.9 - $32.57 $286,330 - $446,209
13,700 New
13,700 $336,000
Q4 2017

Feb 14, 2018

SELL
$21.56 - $28.14 $4.02 Million - $5.25 Million
-186,640 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$20.44 - $25.65 $3.81 Million - $4.79 Million
186,640
186,640 $3.91 Million

Others Institutions Holding ALBO

About ALBIREO PHARMA, INC.


  • Ticker ALBO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 19,612,500
  • Description
  • Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...
More about ALBO
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.